Autologous stem cell transplantation is still an experimental approach for patients with autoimmune diseases. We report here on five patients (relapsing polychondritis n = 1, systemic lupus erythematosus n = 3, systemic sclerosis n = 1), who failed multiple conventional therapeutic strategies and had active life-threatening disease at the time of transplant. Peripheral stem cells were mobilized with Cyclophosphamide 2 g/m 2 and G-CSF. The transplant was CD34 positive selected by CliniMacs and contained 2.4 to 7.3 × 10 6 CD34+/kg b.w. and 1.0 to 1.6 × 10 4 CD3/kg b.w. The conditioning regimen included 200 mg/kg Cyclophosphamide and for in vivo T-cell depletion 90 mg/kg ATG. Four out of 5 patients are already transplanted. The patients received anti-bacterial and antiviral prophylaxis and developed no life-threatening infections post transplant. Three out of 4 patients with a follow-up time between 3 and 9 months after transplant are in clinical and serological remission. The reconstitution of the immune system revealed a Thelper memory cell reconstitution. For 1 out of 4 patients it is too early for evaluation. In conclusion: In vivo/ex vivo T-cell depletion of autologous stem cell transplants induce clinical and serological remission in patients with refractory autoimmune disease. The duration of the remissions is unknown and has to be studied. If relapses should occur, allogeneic transplantation has to be considered to induce a graft-vs-autoimmunity effect and probably cure of disease. In Freiburg 4 SSc patients have been treated until now. PBSC were harvested after 4 gm/m 2 cyclophosphamide and filgrastim mobilisation followed by CD34+ selection. Conditioning with 4 × 50 mg/kg cyclophosphamide and PBSCT was well tolerated in the first 3 patients. The 4th patient developed reversable pulmonary edema and absolute arrhythmia after mobilisation cyclophosphamide. Therefore in this patient we used Fludarabin, BCNU and Thiotepa for conditioning which was well tolerated. Clinical and objective responses with improvement in skin score, decrease of ANA and Scl-70 antibody titers as well as stable lung function in previously progressive patients were seen. With a follow-up of more than 3 years all patients are in stable PR with marked improvement of quality of life. This form of treatment may pose an alternative to standard regimen. Disease related toxicities should be considered seriously. Randomized trials should prove the role of high-dose immunosuppressive therapy in autoimmune disease.
